Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06557421
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients (STOP VEN)
Sponsor: Institut Paoli-Calmettes
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine Venetoclax
Updated 3 times since 2024 Last updated: Mar 11, 2026 Started: Feb 4, 2026 Primary completion: Nov 1, 2028 Completion: Nov 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Acute Myeloid Leukemia and is currently actively recruiting participants. Institut Paoli-Calmettes leads this study, which shows 3 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
3 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Jul 2025 — Mar 2026 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Jul 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Institut Paoli-Calmettes
Data source: Institut Paoli-Calmettes
For direct contact, visit the study record on ClinicalTrials.gov .